Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 15/20 | 0.68 |
| ▸ | FYN | P06241 | 2/20 | 0.61 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4163050 | 1.00 | MAP3K11 (0.68) | MAP3K11FYNLRRK2MTOR | |
| SCHEMBL4279515 | 1.00 | MAP3K11 (0.68) | MAP3K11FYNLRRK2MTOR | |
| SCHEMBL975509 | 0.85 | FYN (0.72) | MAP3K11FYNMTOR | |
| SCHEMBL723157 | 0.81 | MAP3K11 (1.00) | MAP3K11FYNLRRK2 | |
| SCHEMBL482133 | 0.80 | FYN (0.63) | MAP3K11FYNMTOR | |
| SCHEMBL482134 | 0.80 | FYN (0.63) | MAP3K11FYNMTOR | |
| SCHEMBL4270835 | 0.80 | FYN (0.82) | MAP3K11FYNLRRK2MTOR | |
| SCHEMBL481671 | 0.80 | FYN (0.71) | MAP3K11FYNMTOR | |
| SCHEMBL481669 | 0.80 | FYN (0.71) | MAP3K11FYNMTOR | |
| SCHEMBL977396 | 0.80 | FYN (0.54) | MAP3K11FYNMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608622-B2 | 1 -Phenylerhyl)-6-(3,4,5-trimethoxyphenyl)- 1 ,3-dihydroimidazo[4,5-b]pyrazin-2-one; | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| US-20060106022-A1 | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106022-A1 | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases | AURKA, AURKC, AURKB | MAP3K11 116/4885FYN 645/4885LRRK2 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.